VANCOUVER, British Columbia, Feb. 28, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer’s disease.
